BioSpace News Archive

Therapeutic Solutions International (TSOI) announced today identification and patent filing of a previously unexpected discovery that responsiveness to JadiCell stem cell therapy appears to correlate with alternations of a specific type of B cell producing the cytokine interleukin-10 and possessing unique surface markers.

Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.

Minerva Biotechnologies, a private company developing 1st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of metastatic breast cancers.

Novotech announced the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

Sarepta Therapeutics, Inc. reported preliminary* fourth quarter and full-year 2022 net product revenues as part of their presentation today at the 41st Annual J.P. Morgan Healthcare Conference.

Calidi Biotherapeutics, Inc. and First Light Acquisition Group announced they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs.

UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announces positive topline results from the IASOS Phase 2b study of oral orismilast in adult patients with moderate to severe psoriasis.

IV BioHoldings, a global leader in liquid biopsy technology specializing in early detection precision diagnostics, debuted its Real Early Detection “R.E.D.” campaign at the 41st annual JP Morgan Healthcare Conference in San Francisco.

Derm-Biome Pharmaceuticals, Inc is pleased to announce that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD) School of Medicine, one of its topical lead compounds produced significant inhibitory effects in an animal model of acne, a common chronic inflammatory skin disease for which there is a significant unmet need.